In this edition of Founder Thesis, Akshay Datt talks with Dr. Anand Anandkumar, CEO and MD of Bugworks Research Inc., a remarkable drug discovery company focused on developing novel broad-spectrum antibiotics and immunotherapies that stand to transform the healthcare ecosystem worldwide.

A veteran in the semiconductor industry with almost two decades of experience, Dr. Anandkumar wears many hats. To mention a few, he is the Vice President of the India Biotech Association & one of the founding members of the India Electronics and Semiconductor Association (IESA).

In 2005, he founded Cellworks which has significantly increased the success rate of cancer treatments by customizing therapy choices. An offshoot of Cellworks, Bugworks originated from the deep resolve to eradicate secondary bacterial infections, a major public health threat in terms of mortality.

Tune in to this episode to hear Dr. Anandkumar speak about how Bugworks has taken a unique path in drug discovery as it attempts to fight the war against rising antibacterial resistance.

What you must not miss!

  • Current drug development challenges
  • Monetizing drug combination therapies
  • AMR and superbugs

In this edition of Founder Thesis, Akshay Datt talks with Dr. Anand Anandkumar, CEO and MD of Bugworks Research Inc., a remarkable drug discovery company focused on developing novel broad-spectrum antibiotics and immunotherapies that stand to transform the healthcare ecosystem worldwide.

A veteran in the semiconductor industry with almost two decades of experience, Dr. Anandkumar wears many hats. To mention a few, he is the Vice President of the India Biotech Association & one of the founding members of the India Electronics and Semiconductor Association (IESA).

In 2005, he founded Cellworks which has significantly increased the success rate of cancer treatments by customizing therapy choices. An offshoot of Cellworks, Bugworks originated from the deep resolve to eradicate secondary bacterial infections, a major public health threat in terms of mortality.

Tune in to this episode to hear Dr. Anandkumar speak about how Bugworks has taken a unique path in drug discovery as it attempts to fight the war against rising antibacterial resistance.

What you must not miss!

  • Current drug development challenges
  • Monetizing drug combination therapies
  • AMR and superbugs
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pocket
Pocket
Share on email
Email

FEATURED GUESTS

Dr. Anand Anandkumar CEO and MD, Bugworks Research Inc.

About Founder Thesis

Candid conversations with some of the most celebrated startup founders of our nation. On Founder Thesis we are on mission to uncover the secrets to building a Unicorn!

HOSTED BY

No data was found

EXPLORE MORE SHOWS

Founder Thesis
Kahaniyon Ka Guccha Podcast
The Spotlight
Upgrade With Nakul